Nabla Bio has entered a new multi-year research collaboration with Takeda to advance AI-driven design of protein therapeutics ...

“High quality, large-scale, fit-for-purpose datasets” continues to be the tagline for artificial intelligence (AI) models aiming to achieve scalable drug discovery to novel targets. While troves of ...

Artificial intelligence-powered protein design promises to transform fields ranging from drug discovery to industrial materials development. But design only gets you so far – every invention also has ...

Knapsack creates a unified workspace that integrates design and coding tools to ensure design and engineering teams are on ...

U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda ...

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical ...

Patent number 3,174,137, which is titled Gut Microbiota Bioactivated PDE4 Inhibitor Precursors, encompasses the composition ...

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

Braskem’s I’m green™ bio-based brand will participate in Sustainable Brands 2025, held in San Diego, Calif., from Oct. 13 to ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...